TY  - GEN
AU  - Kobashigawa,J
AU  - David,K
AU  - Morris,J
AU  - Chu,A H
AU  - Steffen,B J
AU  - Gotz,V P
AU  - Gordon,R D
TI  - Daclizumab is associated with decreased rejection and no increased mortality in cardiac transplant patients receiving MMF, cyclosporine, and corticosteroids
SN  - 0041-1345
PY  - 2005///0926
KW  - Adult
KW  - Antibodies, Monoclonal
KW  - therapeutic use
KW  - Antibodies, Monoclonal, Humanized
KW  - Daclizumab
KW  - Drug Therapy, Combination
KW  - Female
KW  - Graft Rejection
KW  - epidemiology
KW  - Heart Transplantation
KW  - immunology
KW  - Humans
KW  - Immunoglobulin G
KW  - Immunosuppressive Agents
KW  - Incidence
KW  - Infections
KW  - Male
KW  - Middle Aged
KW  - Multivariate Analysis
KW  - Postoperative Complications
KW  - classification
KW  - Registries
KW  - Survival Analysis
KW  - Time Factors
KW  - United States
N1  - Publication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1016/j.transproceed.2004.12.135
ER  -